innoviris.brussels · Web viewToday, with the growth of big data in biomedical and healthcare...

Joint R&D Project Call

Call 2019

From therapeutic medicine to predictive medicinePrediction, Prevention, Identification

Rules and guidelines

Expression of Interest form

Connect form

Deadline: May 3 rd 2019 at 2:00 pm

Submission of 2 paper copies by post and 1 electronic (Word) version at

[email protected], [email protected] and [email protected]

More info?

Jonathan [email protected]

+32 2 600 50 52

Aiko [email protected]

+32 2 600 50 27

Joint R&D Project Call 2019Expression of Interest Form

/ 27

mailto:[email protected]



After a first edition dedicated to artificial intelligence and a second to distributed and decentralized systems, Innoviris is pleased to announce the third edition of its Joint R&D Project Call (formerly known as Team Up). The objective of the program is to foster collaboration between academia and industry in the Brussels-Capital Region. The program involves active participation of both academic units and industrial teams with an aim of strengthening knowledge, transferring IP from academic research to the industry and turning it into solutions that lead to new business opportunities. Companies will acquire the knowledge they lack/require and integrate the state-of-the-art, while academics will find real-world use cases to apply their findings. This year’s call will focus on another strategic priority of the Region, namely health and more precisely:

Nowadays, medicine is not just therapeutic but integrates more and more predictive dimensions. In addition to providing care, it can predict, sometimes well in advance, the conditions that will affect a specific individual, allowing them to implement prevention strategies. Then, after the essential step of detecting and identifying the disease, it is able to predict the patient's therapeutic response to the various treatments envisaged. On a larger scale, prediction can also extend to predicting the spread of epidemics. Prediction, Prevention and Identification will thus be the three pillars of the call, each targeting actors from various fields such as biotechnology, information technology or imaging.

Predictive medicine is finding fertile ground in the Brussels-Capital Region, which is rich in academic and industrial skills in these fields. This promising domain remains however in its infancy and poses many challenges that this call aims at addressing.


/ 27

The three pillars of predictive medicine: Scope of the Joint R&D Project Call

Our call identifies three pillars of predictive medicine: prediction, prevention and identification. Note that these pillars are not strictly separated and that a project can tackle either one or several pillars simultaneously.

In this section, each pillar is associated with a definition that delineates the limits of the scope. Each pillar is illustrated by a series of examples and challenges. Please note that these examples and challenges are not meant to restrict the scope of the call. Rather, they were chosen to show that each pillar can be tackled by a wide range of disciplines. Any project that incorporates at least one pillar is welcome, regardless of the technology or discipline involved, as long as it aims to strengthen knowledge, to transfer IP from academic research to the industry and to lead to new business opportunities.

Pillar I: Prediction

DefinitionPrediction is the ability to determine the risk of an individual or a population developing a specific condition in a given future time frame.

Examples : At the individual scale, in the biotechnology and biopharmaceutical sector, biomarkers are the focus

of attention. Once identified and associated with the understanding of their transcription and the mechanisms that modulate their expression, biomarkers are tools for predicting the development of a condition.

Medical devices are booming, with the development of mobile health devices that continuously record a wide range of biological parameters. The IT sector, by integrating and interpreting the collected data, can make it possible to detect the early signs of disease. At the population scale, mathematical simulation models in epidemiology integrating several data sources can predict the spread of a disease.

Pillar II : Prevention

DefinitionPrevention, which acts prior to the disease developing, is the mitigation, the delay or the avoidance of diseases or disabilities (e. g. vaccination and action on risk factors).

Examples :


/ 27

In the field of nutrition, new probiotic-based products are developed to balance the intestinal flora and microbiota. This strengthens the immune system response and prevents inflammation.

The combination of Big Data, AI and mobile technologies enables healthy individuals to better monitor and improve their health and lifestyle1.

By improving fall or fall risk situation monitoring, we limit intra-hospital incidents and the risk of serious injuries among elderly patients.

Pillar III : Identification

DefinitionThe third pillar encompasses the different steps of detection and identification of the disease and of the most efficient treatment for a particular patient. ExamplesFrom imagery, to genotyping, to cell cultures, identification and diagnostic tests involve multiple high-level technologies. Moreover, today, we observe spectacular progress in the field of theranostics. These new tools combine precise diagnostic tests and the choice of the best cancer drug. For treatment selection, Companion diagnostics are developed to determine the applicability of a therapeutic drug to a specific person.

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332111/


/ 27

Inspirational challenges:

The following series of challenges is meant to inspire potential applicants, not to restrict the scope of the call.

Mobile Health (mHealth) technologies are able to continuously record and interpret individual-level human behavior and physiology in situ by using data from smartphones and other personal digital devices. Many challenges must be tackled in this rapidly evolving sector.

- To ensure the precision, accuracy and stability of the devices, further R&D efforts must be dedicated to dynamic data acquisition, transmission and provision (in real-time) to medical professionals.

- A useful and effective mHealth device must be technically sound but also requires thoughtful design and consideration of the trade-offs associated with the use of the technology. Thus, the development of these devices requires collaboration between multi-disciplinary teams, from clinical experts (e.g. clinical psychologists, physician-scientists, pharmacologists) to technologists (e.g. software programmers, health systems engineers, computer scientists), at all phases of a project.

- The development of new clinical evaluation strategies is needed to rapidly and effectively validate the efficacy and the effectiveness of mhealth devices.

Producing accurate prediction of infectious disease incidence at short and long time scales will improve public health response to outbreaks. Today, with the growth of big data in biomedical and healthcare communities, combined with the maturity of disease surveillance and reporting systems, real-time disease forecasting has become a realistic goal. However,

- Incomplete medical data reduces analysis accurary. To tackle these limitations, machine learning algorithms for effective prediction of disease outbreak must be streamlined, new modified prediction models over real-life hospital data have to be explored, novel approaches to overcome the problem of incomplete data need to be considered.2

- On the other hand, creating predictions in real-time still poses logistical challenges as raw data must be made available in a standard format for processing into analysis datasets. Historical data is also needed to train the prediction model(s).

- A computational infrastructure is needed to transform and/or merge raw data into the analysis dataset and to run the models

- Analytical challenges include appropriate model training, selection, and validation, considering adjustments for delayed or incomplete case reporting. Depending on the methods used, additional statistical work may be necessary to accurately report uncertainty in the reported predictions3.

A disease biomarker is a traceable and characterized substance that is used to diagnose various phases of diseases, monitor severities of diseases and responses to therapies, and is a predictor of prognosis of patients and likely responses to therapy. Increasing numbers of such biomarkers are being discovered and identified, raising many challenges :

2 https://ieeexplore.ieee.org/document/79123153 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909288/


/ 27

- Determining the disease-associated specificity, sensitivity, traceability, stability, repeatability and reliability through the use of the “Omic” sciences including genomics, proteomics, metabolomics, pharmacogenomics, transcriptomics, and other high-throughput methodologies.

- Evaluating and validating the biomarker by using computational biology, high-throughput image analysis, molecular genetics, mathematical medicine and biology, protein expression and profiling, and systems biology.

- Understanding the role of biomarker candidates in therapeutic strategies through a new research domain called ‘Clinical bioinformatics’ which combines clinical measurements and signs with human tissue-generated bioinformatics.

- Finding new biomarkers able to determine the applicability of a treatment to a specific person (Companion diagnostics) by improving new high-throughput in vitro diagnostics platforms permitting the simultaneous assessment of multiple analytes, NGS and MS proteomics.

- It has been scientifically demonstrated that the mere detection of a therapeutic target is not sufficient to predict drug efficacy. Additional data must now also be provided to further assess resistance to the drug4.

The microbial content of the human gut (gut microbiota) has shown great potential for diagnosis, disease prediction and therapeutic intervention. These advances are accompanied by the development of new food and technologies that will feed our gut microbiota and influence their distribution. Indeed, probiotics, prebiotics, xenobiotics, fecal transplants are all ways to modify our microbiota and possibly prevent the pathologies for which it could be responsible.

- Significant work remains to be done to precisely define the composition of a "healthy" microbiota. Indeed, analysis of human microbiota was until recently still performed by culture-dependent methodologies, limiting the outputs to the cultivable species. The availability of novel tools, primarily next-generation sequencing (NGS), enable the assessment of genes and genomes contained within complex microbial communities, opening the door for new discoveries and applications.

- A crucial step is the investigation of the relationship between the gut microbiota and disease in order to better prevent and treat the development of disease.

- In the agri-food industry, the production of prebiotics and probiotics at industrial scale faces several major challenges, including the search for economical and abundant raw materials for prebiotic production, the low-cost production of probiotics and the improvement of probiotic viability after storage or during the manufacturing process of the functional food5.

Vaccines have provided some of the greatest successes in the history of medicine, including the eradication of smallpox, the near eradication of polio, and the prevention of considerable morbidity and mortality from numerous infectious diseases each year. However,

4 http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2014-0063-ED5 https://www.ncbi.nlm.nih.gov/pubmed/21445871


/ 27

- Past strategies for vaccine development are unlikely to succeed in the future against major global diseases such as AIDS, tuberculosis, and malaria. Indeed, for such diseases, the correlates of protection are poorly defined, and the pathogens evade immune detection and/or exhibit extensive genetic variability. The limitations of animal models to predict human immune responses to vaccines, coupled with low success rates for vaccine development compared with biopharmaceuticals, suggest that new paradigms must be adopted to accelerate vaccine development6.

Eligibility conditions (as from the Expression of Interest stage): The project must involve at least one research organization (university, university colleges or research

center) having at least one head office in the Brussels-Capital Region AND one company whose relevant R&D activities are based in the Brussels-Capital Region;

The project may thus involve the participation of more than one research organization and more than one company. However, the balance of efforts (men-months) between academia and industry must respect a 1/3 – 2/3 balance; i.e. the sum of efforts of all partners from academia or industry must not be greater than 2/3 the total efforts of the project;

Companies must be in an healthy financial situation as defined by EU legislation (cf. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0651 p19, §18);

Companies must demonstrate their ability to finance their share in the project; Companies must have fulfilled their obligations in the context of previous support initiatives allocated

by the Region; Projects must fall within the scope of the defined call topic; Expected outcomes of the project must have a favorable impact for the partners in the Brussels Region

(jobs, expertise, growth etc…).

6 http://science.sciencemag.org/content/340/6136/1232910


/ 27

http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0651

http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0651

Work program and Funding: Academic teams are expected to perform world-class research activities while companies are expected

to put the research results into practice; Project duration must be between one and three years; Funding rates are given by the following Table:

Micro and Small Entreprise 60%

Medium Entreprise 50%

Large Entreprise 40%

Research Organisations 100%

Since writing a solid full proposal is time and resource consuming and may constitute a barrier to entry, Innoviris is making available a Connect subsidy to cover part of the associated costs. This subsidy amounts to a maximum of 7500 Euros per partner (with a limit of 25.000 Euros per consortium). We encourage companies to dedicate part of this subsidy to investigate the IP aspects of the collaboration. Only consortia submitting a full proposal will receive the subsidy. Interested partners will fill in the Connect application form in annex of this document.

Evaluation Criteria:

Innovative character of the project ; Excellence of the research program, contributions beyond the state-of-the-art ; Quality of the execution plan (work program, methodology, expertise of the teams, planning); Level of technological transfer from academia to industry and synergies between the partners; Valorization of the project outcomes from a business perspective ; Impact of the project outcomes on economical and societal challenges of the Brussels Region

Schedule:

1rst February 2019: Launch of the call for expressions of interests; 26th February 2019: Optional : Innoviris organizes a matchmaking event to help form consortia and

sketch project ideas. This event will also be the occasion for potential applicants to get answers to their


/ 27

questions and interact with advisors from Innoviris. See the Innoviris website for further details and registration.

3rd May 2019, 2pm: Deadline for Innoviris to receive:o the expressions of interest forms (2 paper versions to be sent to Innoviris, Chaussée de

Charleroi 110, 1060 Brussels & 1 electronic (Word) version to be sent to: [email protected] , [email protected] and [email protected])

o Optional: the CONNECT form (appended to the above expressions of interest forms); 31rst May 2019: Invitation to submit full proposals for consortia whose expression of interest has been

retained. The selection of the expressions of interest will be based on the eligibility conditions. However, in the case of a high number of applications in regards to the available budget, Innoviris may go beyond the sole eligibility criteria and use the evaluation criteria (cf. above) to retain only the best eligible proposals;

4th October 2019, 2pm: Deadline for Innoviris to receive:o the full proposals forms (2 paper versions to be sent to Innoviris, Chaussée de Charleroi 110,

1060 Brussels & 1 electronic (Word) version to be sent to: [email protected] , [email protected] and [email protected]);

In the course of November 2019 and December 2019: oral defense in front of a jury of experts and Innoviris – Innoviris evaluates the valorisation aspects while the experts assess the technical side of the project;

Based on the evaluation, Innoviris will recommend that the Brussels Government fund the best ranked projects as allowed by the budget allocated to the call.

Between 1st February 2020 and 1st June 2020: projects start.

IP strategy:

In an open innovation program, it is fundamental for the partners to engage early in negotiations on the IP (intellectual property) aspects of their project. Innoviris asks the applicants to have agreed on a high level IP strategy at the time of the expression of interest submission. Furthermore, a signed consortium agreement will have to be submitted together with the full proposal. The consortium agreement should set the framework for a successful project implementation. It is a private agreement between the partners, which sets out rights and obligations amongst themselves, and does not involve Innoviris. Amongst others, the agreement will define the way an academic partner will be remunerated in the case of an actual IP transfer to an industrial partner.

Should you have any question, feel free to contact Innoviris:Jonathan Duplicy, [email protected], 02/600.50.52


/ 27








Aiko Gryspeirt, [email protected], 02/600.50.27


/ 27


Expression of Interest formDeadline: May 3rd at 2:00 pm

[English is the preferred language but submissions in French and Dutch are welcome]


/ 27

A. One-page overview

Explanatory note to be deleted

Please fit the content into one page

Project Title: …………………………………………………………………………

Project Keywords: …………………………………………………………………………

Project Duration: xx months

Project Partners: …………………………………………………………………………

…………………………………………………………………………

…………………………………………………………………………

Project Summary [NB. This summary might be use to anticipate the selection of experts. Be comprehensive]:………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..


/ 27


/ 27

B. Consortium presentation


Please copy/paste the relevant tables if the consortium is made up of more than two partners. Each table should fit in one page.

B.1. Research Organisation(s)

Research Organisation Name: ………………………….

Research unit Name: …………………………Research activities: …………………………………………………………………………..…………………………………………………………………………………………………………..…………………………………………………………………………………………………………..

Persons in charge Person legally authorised to bind the organisation: Name: ………………………… Position: …………………………

Administrative manager for the project:Name: ………………………… Position: …………………………E-mail: ………………………… Phone: …………………………

Technical and scientific manager for the project:Name: ………………………… Position: …………………………E-mail: ………………………… Phone: …………………………

Role in the project Describe the role of the Partner in the project and the specific skills he will bring to the project

Joint R&D Project Call 2019 CONNECT Form

/ 27

B.2. Company(ies)

Company Name: ………………………….Company N°: ………………………….Bank account N°: …………………………. [Please append a bank identification document ]Sector: …………………………Size: micro-small-medium-large enterprise

Company Division Name: …………………………R&D activities: …………………………………………………………………………..…………………………………………………………………………………………………………..…………………………………………………………………………………………………………..…………………………………………………………………………………………………………..

Persons in charge Person legally authorised to bind the organisation: Name: ………………………… Position: …………………………

Administrative manager for the project:Name: ………………………… Position: …………………………E-mail: ………………………… Phone: …………………………

Technical and scientific manager for the project:Name: ………………………… Position: …………………………E-mail: ………………………… Phone: …………………………

Role in the project Describe the role of the Partner in the project and the specific skills he will bring to the project


/ 27

C. Project Presentation

C.1. Objectives

2 pages:………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..

C.2. Innovative character

1 page: Explain how the project is innovative both from an industrial and an academic point of view………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..


/ 27

………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..

C.3. Match with the call topic

10 lines: Explain how the project is aligned with the call topic………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..

C.4. Valorisation of the project outcomes

1 page: Explain how results will be valorised both from a business and an academic point of view and the impact it will have for the partners in the Brussels Region (jobs, expertise, growth etc…).………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..………………………………………………………………………………………………………………………………………………………………..


/ 27

C.5. Budget estimate

-Total Budget estimate: xx €-Total Subsidy estimate: xx €


Please copy/paste the table below and rename the title to cover the whole consortium. The budget is at this stage not definitive and will be readjusted at the Full Project Proposal

stage.

Partner XEstimated effort (man.month) X MMEstimated budget 0 €Funding Rate X %Subsidy 0 €


/ 27

D. Signatures


Please copy/paste the table below and rename the title to cover the whole consortium.

Partner X

By signing the document, I certify that (please tick the boxes):

□ I have read and agree on the program guidelines ; □ All the information provided in this document are correct ; □ The IP aspects of the project have been discussed with the other partners and an IP strategy

was agreed upon ; □ I am aware that a signed consortium agreement will be requested concurrently to the

submission of the full proposal (in the case where the expression of interest is retained).

Name (legal representative): …………………………..

Position: ……………………….

Signature & date:


/ 27

CONNECT 2019

Request for Subsidy

One form per participant

Name of Applicant

« Title of project »

Type of Partner

Academia Entreprise

Budget XXXX €

Funding rate %

Subsidy requested (max 7500€) €

Period June 1st 2019 – October 4th 2019


/ 27

General Context:

In order to encourage the teaming up of academic partners with enterprises to set up interesting R&D projects in the domain of Predictive Medicine, Innoviris offers the possibility to cover parts of the costs associated with their preparation. A maximum amount of 7.500€ can be granted per partner in the consortium (with a total cap of 25.000€ per consortium) in order to cover the personnel costs of the person(s) in charge of discussing, negotiating and writing the proposals, but also, if needed, legal advice on IP issues.

Process:

The application form for setting-up Joint R&D projects must be submitted to INNOVIRIS together with Expression of Interest-EoI form by May 3rd, 2pm;

If your Expression of Interest is selected and the consortium is invited to introduce a Full Project Proposal (FPP), your CONNECT grant will be accepted upon submission of the latter. Should no FPP be submitted, the partners will not be eligible for the CONNECT grant, and the costs incurred in the phase between EoI and FPP will not be covered; Your CONNECT request will also be automatically denied if your Expression of Interest is not selected.

Each partner of the consortium can submit a CONNECT form, and the consortium shall ensure that the maximum amount does not exceed the limit;

The CONNECT grant covers the period between the submission of the Expression of Interest and the submission of the FPP;

The expenses covered can extend to the day on which the final project proposal is submitted to Innoviris, i.e. the Full Proposal deadline of the Joint R&D Project call;

Cost statements shall be provided alongside the FPP;

For companies only: As this subsidy is considered as a de minimis aid, a sworn statement shall be introduced alongside the CONNECT form (See Annex 1).

.


/ 27

E. Detailed description of the preparatory work and necessary actions for setting up the project

Informative note to be deleted

Please describe in detail all actions that shall be undertaken for setting up the Full Proposal, and for which you request funding from the Region (drafting of Full Proposal, meetings…).

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… (Max 2 pages)


/ 27

F. Budget of the project set-up


Copy-paste the hereafter table

Draw up the budget for the project preparation for the relevant period (including sub-contractors), using the template provided

If your organisation is liable for VAT, the expenses to be taken into consideration are ex VAT.

Admissible costs cover:

staff costs incurred in the context of setting up the project, subcontracted legal advice on IP.

Only expenses incurred after Innoviris has issued a positive decision on the Expression of Interest and after submission of the Full Proposal will be covered.

Staff costs:These include expenses relating to the remuneration of the team in charge of setting up the project (local coordinators, researchers, etc.). The applicants must distinguish between employees (1.1) and self-employed workers (1.2). The average man/month cost shall be considered as an average of the unit cost for the different members of the team (local coordinators, researchers, etc..) of the specific partner. Each amount must be calculated on the basis of an average of costs, meaning that salary fiches or invoices must be submitted at the stage when expenses are verified.

General costs:This is a fixed amount to cover additional costs incurred as a result of the setting-up of the project (secretariat, bookkeeping, telecommunications, inspections, travel in Belgium, etc.). The fixed amount is set at 10% of the amount for salaried staff costs (1.1).

Sub-contractor costs:These costs cover the expenses linked with legal consulting services in order to solve IP questions during the preparation of the project.

Funding rate: 70% for enterprises 100% for research organisations


/ 27

1. Staff costs €1.1 Employee/salaried staff €

Number of Man/months for the preparation of the project Average Man-month

cost7

Total

€

1.2 Self-employed staff €Number of Man/months for the preparation of the project Average

Man-month cost

Total

€

2. General costs €10 % of Salaried staff costs

3. Sub-contractors €Legal IP services €

TOTALINTERVENTION RATE

€%

SUBSIDY REQUESTED €

7 This represents an average cost for the various types of profiles working on the preparation of the Full Proposal


/ 27

G. Autorisation and signature

By signing the document, I certify that (please tick the boxes):

□ I have read and agree on the program guidelines ; □ All the information provided in this document is correct ; □ I authorise Innoviris to proceed with the necessary investigation for the examination of this application

and certify that the information contained in this form is true and correct.

Signature by the legal representative:

Name: …………………………..

Position: ……………………….

Signature & date:


/ 27

H. Annex 1- Declaration of Honour (only to be filled in by companies)

Sworn Statement

I, Mrs/Ms/Mr …..., in my capacity of administrator, manager, director of the company :

Name of Company: ….

Address: …

Company Number: …

Having submitted a request for funding for the project entitled “…..” introduced within the Joint R&D Call 2019 on Predictive Medicine.

Subsidy requested: ……. €

This intervention of the Brussels-Capital Region is granted to me by reference to the Regulation 1407/2013 of December, 18th 2013 on the application of Articles 107 and 108 of the Treaty on the Functioning of the European Union to de minimis aids (published in OJ number L 352 of December 24th 2013) of the European Commission.

I hereby I acknowledge that the amount of the subsidy mentioned above does not bring the total amount of aid already granted to me under the said Regulation, to an amount exceeding € 200,000 over a period of 3 fiscal years.

This ceiling applies irrespective of the form, purpose of the aid and the nature of the subsidising entity. The amount of aid granted in this case must therefore be taken into account if I receive further de minimis aid at a later stage.

I hereby declare on my honour that the present statement is sincere and complete

Date : Signature


/ 27


/ 27

innoviris.brussels · Web viewToday, with the growth of big data in biomedical and healthcare...

Documents

Transcript of innoviris.brussels · Web viewToday, with the growth of big data in biomedical and healthcare...